Exchange: NASDAQ·Updated 02:32 PM EDT
TCRX logo

TCRX Tscan Therapeutics Inc

$0.3701
$0.011
(2.89%)
Today
Reported EarningsAug 12
Mkt Cap$25.83M
Vol2.42M

About TCRX

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Waltham, MA.
86

Extremely Bullish Sentiment

How do you feel about TCRX?

Advertisement|Remove ads.